Videos

Global Standardization of Flow Cytometry Results with AI Systems

Invivoscribe Marketing2022-05-09T03:56:30+00:00December 8th, 2021|2021 Videos, 2021 Webinars, Featured Videos, Videos, Webinars|

FEATURED PRESENTERS
Meindert Niemeijer, Chief Information Officer / Julian D'Angelo, Bioinformatics Manager

Complementary Value of MRD Assessments by NGS and MFC for the Study of Hematologic Malignancies

Invivoscribe Marketing2022-05-09T03:52:35+00:00December 1st, 2020|2020 Videos, 2020 Webinars, Videos, Webinars|

FEATURED PRESENTERS
Ola Landgren, PhD, MD / Swati Shah, MD

Artificial Intelligence (AI) and other Data Science Applications in Molecular Pathology

Invivoscribe Marketing2022-05-09T03:52:39+00:00November 16th, 2020|2020 Videos, Videos|

FEATURED PRESENTER
Dr. Bradley Patay

Clinical Utility of NGS in Lymphoid Malignancies including Minimal Residual Disease (MRD) testing

Invivoscribe Marketing2022-05-09T03:52:41+00:00November 16th, 2020|2020 Videos, Videos|

FEATURED PRESENTERS
Yury Monczak, Ph.D / Ryan J. Schmidt, MD, PhD

Clinical Utility of NGS in Lymphoid Malignancies

Invivoscribe Marketing2022-05-09T03:52:44+00:00February 27th, 2020|2020 Videos, 2020 Webinars, Videos, Webinars|

FEATURED PRESENTERS
Yury Monczak, PhD / Bevan Tandon, MD

Latest Videos

Global Standardization of Flow Cytometry Results with AI Systems

FEATURED PRESENTERS
Meindert Niemeijer, Chief Information Officer / Julian D'Angelo, Bioinformatics Manager

December 8th, 2021|2021 Videos, 2021 Webinars, Featured Videos, Videos, Webinars|

Complementary Value of MRD Assessments by NGS and MFC for the Study of Hematologic Malignancies

FEATURED PRESENTERS
Ola Landgren, PhD, MD / Swati Shah, MD

December 1st, 2020|2020 Videos, 2020 Webinars, Videos, Webinars|

Artificial Intelligence (AI) and other Data Science Applications in Molecular Pathology

FEATURED PRESENTER
Dr. Bradley Patay

November 16th, 2020|2020 Videos, Videos|

Clinical Utility of NGS in Lymphoid Malignancies including Minimal Residual Disease (MRD) testing

FEATURED PRESENTERS
Yury Monczak, Ph.D / Ryan J. Schmidt, MD, PhD

November 16th, 2020|2020 Videos, Videos|

Clinical Utility of NGS in Lymphoid Malignancies

FEATURED PRESENTERS
Yury Monczak, PhD / Bevan Tandon, MD

February 27th, 2020|2020 Videos, 2020 Webinars, Videos, Webinars|

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

Videos

Videos

Featured Videos

Global Standardization of Flow Cytometry Results with AI Systems

Complementary Value of MRD Assessments by NGS and MFC for the Study of Hematologic Malignancies

Artificial Intelligence (AI) and other Data Science Applications in Molecular Pathology

Clinical Utility of NGS in Lymphoid Malignancies including Minimal Residual Disease (MRD) testing

Clinical Utility of NGS in Lymphoid Malignancies

Latest Videos

Global Standardization of Flow Cytometry Results with AI Systems

Complementary Value of MRD Assessments by NGS and MFC for the Study of Hematologic Malignancies

Artificial Intelligence (AI) and other Data Science Applications in Molecular Pathology

Clinical Utility of NGS in Lymphoid Malignancies including Minimal Residual Disease (MRD) testing

Clinical Utility of NGS in Lymphoid Malignancies

Title

Global Search

SEARCH BY KEYWORD

Global Search

SEARCH BY KEYWORD

Looking for Product Documents?
Try our New Document Search Feature ⟶

Looking for Product Documents?
Try our New Document Search Feature ⟶

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021 Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

Videos

Videos

Featured Videos

Global Standardization of Flow Cytometry Results with AI Systems

Complementary Value of MRD Assessments by NGS and MFC for the Study of Hematologic Malignancies

Artificial Intelligence (AI) and other Data Science Applications in Molecular Pathology

Clinical Utility of NGS in Lymphoid Malignancies including Minimal Residual Disease (MRD) testing

Clinical Utility of NGS in Lymphoid Malignancies

Latest Videos

Global Standardization of Flow Cytometry Results with AI Systems

Complementary Value of MRD Assessments by NGS and MFC for the Study of Hematologic Malignancies

Artificial Intelligence (AI) and other Data Science Applications in Molecular Pathology

Clinical Utility of NGS in Lymphoid Malignancies including Minimal Residual Disease (MRD) testing

Clinical Utility of NGS in Lymphoid Malignancies

Title

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing